MA39422B1 - Modulateurs de cot et procédés d'utilisation associés - Google Patents

Modulateurs de cot et procédés d'utilisation associés

Info

Publication number
MA39422B1
MA39422B1 MA39422A MA39422A MA39422B1 MA 39422 B1 MA39422 B1 MA 39422B1 MA 39422 A MA39422 A MA 39422A MA 39422 A MA39422 A MA 39422A MA 39422 B1 MA39422 B1 MA 39422B1
Authority
MA
Morocco
Prior art keywords
associated methods
modulators
cost
cost modulators
methods
Prior art date
Application number
MA39422A
Other languages
English (en)
Other versions
MA39422A (fr
Inventor
Jeromy Cottell
John Link
James Taylor
Elizabeth Bacon
Gary Phillips
Musong Kim
Kirk Stevens
William Watkins
Gayatri Balan
Chien-Hung Chou
Christopher Clark
Thorsten Kirschberg
Scott Schroeder
Neil Squires
Nathan Wright
Sheila Zipfel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA39422A publication Critical patent/MA39422A/fr
Publication of MA39422B1 publication Critical patent/MA39422B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

La présente description concerne en général les modulateurs de cot (cancer osaka thyroïde) et les méthodes d'utilisation et de fabrication de celles-ci.
MA39422A 2015-07-06 2016-06-30 Modulateurs de cot et procédés d'utilisation associés MA39422B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189158P 2015-07-06 2015-07-06
US201562269060P 2015-12-17 2015-12-17
EP16738976.6A EP3191470B1 (fr) 2015-07-06 2016-06-30 Modulateurs de cot et procédés d'utilisation associés

Publications (2)

Publication Number Publication Date
MA39422A MA39422A (fr) 2017-07-19
MA39422B1 true MA39422B1 (fr) 2019-03-29

Family

ID=56411943

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39422A MA39422B1 (fr) 2015-07-06 2016-06-30 Modulateurs de cot et procédés d'utilisation associés

Country Status (40)

Country Link
US (7) US20170008905A1 (fr)
EP (3) EP3456717B1 (fr)
JP (6) JP6430060B2 (fr)
KR (5) KR101974793B1 (fr)
CN (3) CN109879859B (fr)
AU (5) AU2016290820B2 (fr)
BR (1) BR102016015656B1 (fr)
CA (1) CA2971640C (fr)
CL (1) CL2017003356A1 (fr)
CO (1) CO2017013351A2 (fr)
CR (1) CR20170599A (fr)
CU (1) CU20170172A7 (fr)
CY (1) CY1121750T1 (fr)
DK (1) DK3191470T3 (fr)
DO (1) DOP2017000311A (fr)
EA (1) EA036788B1 (fr)
EC (1) ECSP17084635A (fr)
ES (2) ES2734713T3 (fr)
HR (1) HRP20190853T1 (fr)
HU (1) HUE043310T2 (fr)
IL (4) IL293770B2 (fr)
LT (1) LT3191470T (fr)
MA (1) MA39422B1 (fr)
ME (1) ME03425B (fr)
MX (1) MX370984B (fr)
MY (1) MY196173A (fr)
NZ (2) NZ738525A (fr)
PE (1) PE20180462A1 (fr)
PH (2) PH12018500031A1 (fr)
PL (2) PL3191470T3 (fr)
PT (2) PT3456717T (fr)
RS (1) RS58639B1 (fr)
SA (1) SA517381350B1 (fr)
SG (1) SG11201702041PA (fr)
SI (2) SI3456717T1 (fr)
SV (1) SV2017005605A (fr)
TW (3) TWI748539B (fr)
UA (1) UA123010C2 (fr)
UY (1) UY36771A (fr)
WO (1) WO2017007689A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
WO2016057931A1 (fr) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluorométhoxylation d'arènes via une migration intramoléculaire du groupe trifluorométhoxy
IL293770B2 (en) 2015-07-06 2023-07-01 Gilead Sciences Inc Modulators of cot and methods of using them
WO2017007694A1 (fr) 2015-07-06 2017-01-12 Gilead Sciences, Inc. 6-amino-quinoline-3-carbonitriles utilisés comme modulateurs de la kinase cot
US10059695B2 (en) 2016-06-30 2018-08-28 Gilead Sciences, Inc. Cot modulators and methods of use thereof
UY37367A (es) 2016-08-19 2018-03-23 Gilead Sciences Inc Nuevos compuestos para uso en el tratamiento de una infección viral y composiciones de los mismos
EA036921B1 (ru) * 2017-02-10 2021-01-15 Джилид Сайэнс, Инк. Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
CN108794516A (zh) * 2017-04-26 2018-11-13 上海时莱生物技术有限公司 硼酸和硼酸酯类化合物及其制备方法和用途
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
AR112413A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
US20200275661A1 (en) * 2017-09-26 2020-09-03 Nippon Soda Co., Ltd. Quinoline compound, and agricultural and horticultural fungicide
PL3752495T3 (pl) 2018-02-15 2024-01-15 Gilead Sciences, Inc. Pochodne pirydynowe i ich zastosowanie do leczenia infekcji hiv
CA3175384A1 (fr) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methodes et intermediaires pour preparer des composes therapeutiques utiles dans le traitement d'une infection virale des retroviridae
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
CN110294660B (zh) * 2018-03-23 2021-09-24 中国农业大学 一种含碳碳三键和/或碳氮三键的不饱和有机化合物的还原氘化方法
CN108658996A (zh) * 2018-06-25 2018-10-16 中国药科大学 一种氘代Fiduxosin的制备方法
TWI814350B (zh) 2018-07-16 2023-09-01 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
TWI770527B (zh) * 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
PL4021904T3 (pl) 2019-08-29 2024-05-13 Idorsia Pharmaceuticals Ltd Pochodne alfa-d-galaktopiranozydu
EP4065116A1 (fr) 2019-11-26 2022-10-05 Gilead Sciences, Inc. Inhibiteurs de capside pour la prévention du vih
CA3175541A1 (fr) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Formes solides de (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile un compose inhibiteur de cot
WO2021202688A1 (fr) * 2020-04-02 2021-10-07 Gilead Sciences, Inc. Procédé de préparation d'un composé inhibiteur de cot
EP4172157A1 (fr) 2020-06-25 2023-05-03 Gilead Sciences, Inc. Inhibiteurs de capside pour le traitement du vih
AU2022228660A1 (en) 2021-03-03 2023-10-19 Idorsia Pharmaceuticals Ltd Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives
TW202345826A (zh) 2021-06-04 2023-12-01 美商基利科學股份有限公司 治療nash之方法
IL308228A (en) * 2021-06-11 2024-01-01 Neuronascent Inc Methods and preparations for lipid formulation of lipophilic treatments small molecules of the heterocyclic type
KR20240113577A (ko) 2021-12-03 2024-07-22 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930837A (en) 1971-12-31 1976-01-06 Ici Australia Limited 3-chloro-5-acetamidaisoquinoline as a herbicide
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4151298A (en) 1977-01-10 1979-04-24 Ciba-Geigy Corporation Anthelmintic compositions
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2634438B2 (ja) 1988-07-26 1997-07-23 三井東圧化学株式会社 不斉ビスオキサゾリルピリジン誘導体およびその製造方法
DE4014171A1 (de) 1990-05-03 1991-11-07 Basf Ag Cyanochinolinverbindungen
GB9310700D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Novel composition
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
NZ503079A (en) 1997-08-28 2002-07-26 Nissan Chemical Ind Ltd Cyanoacrylate-containing antibacterial and antifungal agents, algicides and antifouling agents
ATE316532T1 (de) 1998-07-10 2006-02-15 Massachusetts Inst Technology Liganden für metalle und metall-katalysiertes verfahren
BRPI9914164B8 (pt) 1998-09-29 2021-05-25 American Cyanamid Co compostos de 3-ciano quinolina
CA2479256A1 (fr) 2002-03-20 2003-10-02 Bristol-Myers Squibb Company Promedicaments phosphates de fluorooxindoles
DE602004010791T2 (de) 2003-03-03 2008-12-04 F. Hoffmann-La Roche Ag 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren
SG145744A1 (en) 2003-08-19 2008-09-29 Wyeth Corp Process for the preparation of 4-amino-3- quinolinecarbonitriles
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
TW200529846A (en) * 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1881981A1 (fr) 2005-05-18 2008-01-30 Wyeth Inhibiteurs de 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile de la tpl2 kinase et procedes de fabrication et d'utilisation de ceux-ci
MX2007014261A (es) * 2005-05-18 2008-01-22 Wyeth Corp Inhibidores de 3-cianoquinolina de cinasa tpl2 y metodos de elaboracion y uso de los mismos.
CN101365684A (zh) 2005-10-28 2009-02-11 艾博特公司 抑制trpv1受体的吲唑衍生物
CN101437519A (zh) 2006-03-31 2009-05-20 艾博特公司 吲唑化合物
WO2008055950A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Nouveaux inhibiteurs de la glutaminyl-cyclase
WO2008092292A1 (fr) 2007-01-17 2008-08-07 The Hong Kong University Of Science And Technology Composés d'isoquinolone servant d'agonistes sélectifs par rapport à des sous-types pour les récepteurs de la mélatonine mt1 et mt2
GB0820856D0 (en) 2008-11-14 2008-12-24 Univ Leuven Kath Novel inhibitors of flavivirus replication
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
GB0922302D0 (en) 2009-12-22 2010-02-03 Imp Innovations Ltd Compounds
EA030276B1 (ru) 2010-03-09 2018-07-31 Дана-Фарбер Кэнсер Инститьют, Инк. Способы идентификации страдающих раком пациентов и лечения рака у пациентов, у которых имеется или развивается резистентность к первой терапии рака
RU2600928C2 (ru) 2010-06-09 2016-10-27 Тяньцзинь Химэй Байо-Тек Ко., Лтд Цианохинолиновые производные
EP2708540B1 (fr) 2011-05-10 2018-07-25 Kyowa Hakko Kirin Co., Ltd. Composé pyrimido-diazépinone
US9173395B2 (en) 2011-07-04 2015-11-03 Bayer Intellectual Property Gmbh Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants
EP2545964A1 (fr) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
MY168930A (en) 2011-10-27 2019-01-09 Taisho Pharmaceutical Co Ltd Azole derivative
DK3329919T3 (da) 2011-11-11 2019-12-09 Gilead Apollo Llc Acc-inhibitorer og anvendelser deraf
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
CN103483363B (zh) 2012-06-13 2016-12-21 上海赛迦化工产品有限公司 多样性的手性氨基硼酸及其制备方法和应用
US20150297573A1 (en) 2012-10-24 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
CN103408572B (zh) 2013-07-12 2015-12-02 上海工程技术大学 手性氨基硼酸衍生物及其制备方法和应用
CN105814013A (zh) 2013-12-12 2016-07-27 卡利拉制药公司 双环烷基化合物及合成
WO2015134710A1 (fr) 2014-03-07 2015-09-11 Kalyra Pharmaceuticals, Inc. Dérivés de propellane et synthèse
WO2016007966A2 (fr) * 2014-07-11 2016-01-14 Northwestern University Échafaudages 2-imidazolyl-pyrimidine en tant qu'inhibiteurs puissants et sélectifs de l'oxyde nitrique synthase neuronale
CA2961605C (fr) 2014-09-17 2023-01-10 Kalyra Pharmaceuticals, Inc. Composes bicycliques
WO2016049069A1 (fr) 2014-09-24 2016-03-31 Gilead Sciences, Inc. Procédé de traitement d'une maladie hépatique
AU2015369668B2 (en) 2014-12-23 2019-04-18 Gilead Sciences, Inc. Processes for preparing ASK1 inhibitors
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
EP3597271A1 (fr) 2015-01-09 2020-01-22 Gilead Apollo, LLC Thérapie combinée à base d'un inhibiteur de l'acc utilisable en vue du traitement de la stéatose hépatique non alcoolique
CN107111844B (zh) 2015-01-16 2021-07-13 3M创新有限公司 用于选择网格动作以改善网格结果的系统和方法
WO2017007694A1 (fr) * 2015-07-06 2017-01-12 Gilead Sciences, Inc. 6-amino-quinoline-3-carbonitriles utilisés comme modulateurs de la kinase cot
IL293770B2 (en) 2015-07-06 2023-07-01 Gilead Sciences Inc Modulators of cot and methods of using them
EP3398598B1 (fr) 2015-12-31 2022-04-06 Hitgen Inc. Dérivé du sulfonamide, son procédé de préparation et son procédé d'utilisation
PL3423456T3 (pl) 2016-03-02 2024-06-17 Gilead Apollo, Llc Formy stałe tienopirymidynodionowego inhibitora acc i sposoby ich produkcji
WO2017221944A1 (fr) 2016-06-21 2017-12-28 パナソニックヘルスケアホールディングス株式会社 Inhibiteur de catalase et procédé de mesure d'analyte utilisant un inhibiteur de catalase
US10059695B2 (en) 2016-06-30 2018-08-28 Gilead Sciences, Inc. Cot modulators and methods of use thereof
CN106512014A (zh) 2016-10-27 2017-03-22 武汉大学 肿瘤进展位点2在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
KR102485620B1 (ko) 2017-03-03 2023-01-09 길리애드 사이언시즈, 인코포레이티드 Acc 억제제 및 그의 고체 형태를 제조하는 방법
EP4424364A2 (fr) 2017-03-28 2024-09-04 Gilead Sciences, Inc. Méthodes de traitement d'une maladie hépatique
WO2018191393A1 (fr) 2017-04-12 2018-10-18 Gilead Sciences, Inc. Méthodes de traitement d'une maladie hépatique
JP7479278B2 (ja) 2017-10-06 2024-05-08 ギリアード サイエンシーズ， インコーポレイテッド Ａｃｃ阻害剤を含む併用療法
EP3927683A1 (fr) 2019-02-19 2021-12-29 Gilead Sciences, Inc. Formes solides d'agonistes de fxr
EP3934615A4 (fr) 2019-03-08 2023-01-25 The Regents Of The University Of California Compositions et méthodes de traitement de l'acné
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
CA3175541A1 (fr) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Formes solides de (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile un compose inhibiteur de cot
WO2021202688A1 (fr) 2020-04-02 2021-10-07 Gilead Sciences, Inc. Procédé de préparation d'un composé inhibiteur de cot
TW202345826A (zh) 2021-06-04 2023-12-01 美商基利科學股份有限公司 治療nash之方法

Also Published As

Publication number Publication date
MX370984B (es) 2020-01-09
CN107922390A (zh) 2018-04-17
DK3191470T3 (en) 2019-04-15
IL266995A (en) 2019-07-31
UY36771A (es) 2017-01-31
JP2018520161A (ja) 2018-07-26
JP2019178178A (ja) 2019-10-17
SI3456717T1 (sl) 2021-08-31
US20170152240A1 (en) 2017-06-01
SA517381350B1 (ar) 2021-03-11
PT3456717T (pt) 2021-05-26
CY1121750T1 (el) 2020-07-31
US20170008905A1 (en) 2017-01-12
AU2022204050A1 (en) 2022-06-30
ES2734713T3 (es) 2019-12-11
IL293770B1 (en) 2023-03-01
KR102443575B1 (ko) 2022-09-16
JP2024100865A (ja) 2024-07-26
KR101974793B1 (ko) 2019-05-02
DOP2017000311A (es) 2018-01-15
AU2020257055A1 (en) 2020-11-12
TW201908305A (zh) 2019-03-01
IL274568A (en) 2020-06-30
AU2020257055B2 (en) 2022-03-31
JP6906021B2 (ja) 2021-07-21
CU20170172A7 (es) 2018-06-05
CA2971640C (fr) 2020-09-22
RS58639B1 (sr) 2019-05-31
KR20240008398A (ko) 2024-01-18
KR20180022982A (ko) 2018-03-06
JP2018193405A (ja) 2018-12-06
CL2017003356A1 (es) 2018-07-06
CO2017013351A2 (es) 2018-05-21
CA2971640A1 (fr) 2017-01-12
WO2017007689A1 (fr) 2017-01-12
JP6781221B2 (ja) 2020-11-04
AU2016290820B2 (en) 2019-03-07
KR102073641B1 (ko) 2020-02-05
JP6430060B2 (ja) 2018-11-28
ECSP17084635A (es) 2018-01-31
CR20170599A (es) 2018-02-28
SV2017005605A (es) 2018-07-18
HUE043310T2 (hu) 2019-08-28
EP3456717A1 (fr) 2019-03-20
AU2019203122A1 (en) 2019-05-30
KR20200013120A (ko) 2020-02-05
EP3896064A1 (fr) 2021-10-20
IL293770A (en) 2022-08-01
PH12018500031B1 (en) 2018-07-09
JP7138155B2 (ja) 2022-09-15
AU2016290820A1 (en) 2018-01-18
EA036788B1 (ru) 2020-12-21
IL293770B2 (en) 2023-07-01
TWI748539B (zh) 2021-12-01
NZ738525A (en) 2019-03-29
JP2022082816A (ja) 2022-06-02
MX2017004737A (es) 2017-06-19
PT3191470T (pt) 2019-06-05
PH12020551397A1 (en) 2021-08-16
PH12018500031A1 (en) 2018-07-09
KR20220129667A (ko) 2022-09-23
AU2024204902A1 (en) 2024-08-01
US20180237455A1 (en) 2018-08-23
US20230002407A1 (en) 2023-01-05
IL256433A (en) 2018-02-28
HRP20190853T1 (hr) 2019-06-28
MY196173A (en) 2023-03-17
LT3191470T (lt) 2019-05-10
SG11201702041PA (en) 2017-04-27
TW202114673A (zh) 2021-04-16
AU2019203122B2 (en) 2020-10-01
JP2021042252A (ja) 2021-03-18
CN109879859A (zh) 2019-06-14
NZ750707A (en) 2023-09-29
US20190248807A1 (en) 2019-08-15
BR102016015656B1 (pt) 2021-11-03
TWI699361B (zh) 2020-07-21
AU2022204050B2 (en) 2024-04-18
SI3191470T1 (sl) 2019-04-30
TWI634112B (zh) 2018-09-01
US20200123172A1 (en) 2020-04-23
TW201712005A (zh) 2017-04-01
MA39422A (fr) 2017-07-19
PL3191470T3 (pl) 2019-08-30
CN114380799A (zh) 2022-04-22
EP3191470B1 (fr) 2019-02-27
IL274568B (en) 2022-07-01
EP3191470A1 (fr) 2017-07-19
IL266995B (en) 2020-05-31
EP3456717B1 (fr) 2021-03-17
IL256433B (en) 2019-06-30
PE20180462A1 (es) 2018-03-06
ES2872076T3 (es) 2021-11-02
EA201792613A1 (ru) 2018-06-29
KR20190045416A (ko) 2019-05-02
ME03425B (fr) 2020-01-20
PL3456717T3 (pl) 2021-10-25
US11066414B2 (en) 2021-07-20
US11905299B2 (en) 2024-02-20
US9878995B2 (en) 2018-01-30
CN107922390B (zh) 2019-05-10
BR102016015656A2 (pt) 2020-09-24
CN109879859B (zh) 2022-01-25
UA123010C2 (uk) 2021-02-03
US20240254137A1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
MA39422B1 (fr) Modulateurs de cot et procédés d'utilisation associés
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
MA43187A (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MY191169A (en) Anti-fcrh5 antibodies
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
EA201990615A1 (ru) Пирролобензодиазепиновые конъюгаты
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
BR112017008666A2 (pt) anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
MA47664A1 (fr) Anticorps anti-c10orf54 et leurs utilisations
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
BR112018071586A2 (pt) uso de beta-agonistas da tireoide
MA39355A1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
CL2020003364A1 (es) Tratamiento antidiabético cardiovascular y renal seguro
UA104973U (uk) Біологічно активна добавка шумілова
EA201792492A1 (ru) Aml-антигены и их применение
MY195448A (en) New Anti-Sirpa Antibodies and Their Therapeutic Applications